Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 6, 2008, Pages 541-550

  Chenu, Frank ^a   David, Denis J P ^b   Leroux Nicollet, Isabelle ^c   Le Maêtre, Erwan ^c   Gardier, Alain M ^b   Bourin, Michel ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

5,7 dihydroxytryptamine creatinine; Mice, knockout; Monoamine oxidase; Receptors; Serotonin

Indexed keywords

5,7 DIHYDROXYTRYPTAMINE; ANPIRTOLINE; ANTIDEPRESSANT AGENT; AUTORECEPTOR; CITALOPRAM; CREATININE; DESIPRAMINE; IMIPRAMINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEUROTRANSMITTER; PAROXETINE; SEROTONIN 1B RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TRITIUM; DOPAMINE; OXADIAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BINDING; FORCED SWIMMING TEST; HIPPOCAMPUS; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PUTAMEN; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

5,7-DIHYDROXYTRYPTAMINE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; CITALOPRAM; DOPAMINE; MALE; MICE; OXADIAZOLES; PIPERAZINES; PIPERIDINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 56349083775     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. De Groote L, Olivier B, Westenberg HG. Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT(1B) autoreceptors: a microdialysis study in knockout mice. Psychopharmacology (Berl) 2002;162:419-24.
2. Gobert A, Rivet JM, Cistarelli L, et al. Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J Neurochem 1997;68:1159-63.
3. Malagie I, Trillat AC, Bourin M, et al. 5-HT1B Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex. J Neurochem 2001;76:865-71.
4. Gardier AM, Trillat AC, Malagie I, et al. [5-HT1B serotonin receptors and antidepressant effects of selective serotonin reuptake inhibitors] [Article in French]. C R Acad Sci III 2001;324:433-41.
5. Redrobe JP, Bourin M. Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) 1999;141:370-7.
6. O'Neill MF, Conway MW. Role of 5-HT(1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 2001;24:391-8.
7. Chenu F, Dailly E, Bourin M. 5-HT1B receptor: A target for antidepressant drugs? Drug Dev Res 2005;65:141-6.
8. Chenu F, Dailly E, Bourin M. Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Eur Neuropsychopharmacol 2007;17:187-93.
9. Thorre K, Ebinger G, Michotte Y. 5-HT4 receptor involvement in the serotonin-enhanced dopamine efflux from the substantia nigra of the freely moving rat: a microdialysis study. Brain Res 1998; 796:117-24.
10. Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 1991;200:1-8.
11. Iyer RN, Bradberry CW. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 1996;277:40-7.
12. Yan QS, Yan SE. Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol 2001; 418:55-64.
13. Yan QS, Zheng SZ, Yan SE. Involvement of 5-HT1B receptors within the ventral tegmental area in regulation of mesolimbic dopaminergic neuronal activity via GABA mechanisms: a study with dual-probe microdialysis. Brain Res 2004;1021:82-91.
14. Redrobe JP, MacSweeney CP, Bourin M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol 1996;318:213-20.
15. David DJ, Bourin M, Hascoet M, et al. Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology (Berl) 2001;153:443-9.
16. Bjorklund A, Baumgarten HG, Rensch A. 5,7-Dihydroxytryptamine: improvement of its selectivity for serotonin neurons in the CNS by pretreatment with desipramine. J Neurochem 1975;24:833-5.
17. Bert L, Favale D, Jego G, et al. Rapid and precise method to locate microdialysis probe implantation in the rodent brain. J Neurosci Methods 2004;140:53-7.
18. Dailly E, Chenu F, Petit-Demouliere B, et al. Specificity and efficacy of noradrenaline, serotonin depletion in discrete brain areas of Swiss mice by neurotoxins. J Neurosci Methods 2006;150:111-5.
19. Naudon L, Leroux-Nicollet I, Boulay D, et al. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum. J Neural Transm 2001;108:431-44.
20. D'Amato RJ, Largent BL, Snowman AM, et al. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 1987;242:364-71.
21. Compan V, Segu L, Buhot MC, et al. Selective increases in serotonin 5-HT1B/1D and 5-HT2A/2C binding sites in adult rat basal ganglia following lesions of serotonergic neurons. Brain Res 1998; 793:103-11.
22. Boissier JR, Simon P. [Action of caffeine on the spontaneous motility of the mouse] [Article in French]. Arch Int Pharmacodyn Ther 1965;158:212-21.
23. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2.
24. Metzenauer P, Barnes NM, Costall B, et al. Anxiolytic-like actions of anpirtoline in a mouse light-dark aversion paradigm. Neuroreport 1992;3:527-9.
25. Stachowiak MK, Stricker EM, Jacoby JH, et al. Increased tryptophan hydroxylase activity in serotonergic nerve terminals spared by 5,7-dihydroxytryptamine. Biochem Pharmacol 1986;35:1241-8.
26. Romero L, Jernej B, Bel N, et al. Basal and stimulated extracellular serotonin concentration in the brain of rats with altered serotonin uptake. Synapse 1998;28:313-21.
27. Daszuta A, Kalen P, Strecker RE, et al. Serotonin neurons grafted to the adult rat hippocampus. II. 5-HT release as studied by intracerebral microdialysis. Brain Res 1989;498:323-32.
28. Chia LG, Ni DR, Cheng FC, et al. Intrastriatal injection of 5,7- dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice. Neurochem Res 1999;24:719-22.
29. Chia LG, Ni DR, Cheng LJ, et al. Effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice. Neurosci Lett 1996;218:67-71.
30. Matsuda T, Somboonthum P, Suzuki M, et al. Antidepressant-like effect by postsynaptic 5-HT1A receptor activation in mice. Eur J Pharmacol 1995;280:235-8.
31. Luscombe GP, Martin KF, Hutchins LJ, et al. Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors. Br J Pharmacol 1993;108:669-77.
32. Rilke O, Will K, Jahkel M, et al. Behavioral and neurochemical effects of anpirtoline and citalopram in isolated and group housed mice. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:1125-44.
33. Manrique C, Segu L, Hery F, et al. Increase of central 5-HT1B binding sites following 5,7-dihydroxytryptamine axotomy in the adult rat. Brain Res 1993;623:345-8.
34. Nelson DL, Herbet A, Bourgoin S, et al. Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol Pharmacol 1978;14:983-95.
35. Eide PK, Hole K. Increased behavioural response to intrathecal serotonin after lesion of serotonergic pathways with 5,7- dihydroxytryptamine seems not to be due to depletion of serotonin. Acta Physiol Scand 1988;134:291-4.
36. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001;155:315-22.
37. De Vries P, Apaydin S, Villalon CM, et al. Interactions of GR127935, a 5-HT(1B/D) receptor ligand, with functional 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol 1997;355:423-30.
38. Arborelius L, Chergui K, Murase S, et al. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 1993;347:353-62.
39. Arborelius L, Nomikos GG, Hacksell U, et al. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 1993;148:465-6.
40. Lejeune F, Millan MJ. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 1998;30:172-80.
41. Guilloux JP, David DJ, Guiard BP, et al. Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice. Neuropsychopharmacology 2006;31:2162-72.